Hot Off the Press – October 12, 2021
Previous studies reported that the NOP/µ receptor partial agonist BU08028 produced antinociception in rodents and non-human primates and is not self-administered by non-human primates, leading to the suggestion that BU08028 can be a promising candidate for opioid addiction treatment. In a buprenorphine-validated rat model of opioid agonist maintenance treatment, we report that chronic BU08028 delivery resulted in sex-dependent beneficial and detrimental effects on some measures of heroin relapse and sex-independent null effects on other relapse measures and heroin choice. We conclude that to the degree that our buprenorphine-validated rat models of heroin relapse and choice predict medication efficacy in humans, our results suggest that mixed NOP/µ receptor partial agonists should not be considered for the treatment of opioid addiction in humans.
In: Br J Pharmacol, 2021, ISSN: 1476-5381.